Horizon doubles down on Krystexxa marketing to physicians with ‘green stuff’ imagery
Horizon’s recent label makeover for 12-year-old gout med Krystexxa is breathing new life into the drug — and its marketing efforts.
In July, Horizon picked up a new FDA-approved label for Krystexxa co-administered with methotrexate. The combination study showed increased effectiveness from 42% to 71% and a massive drop in infusion reactions, down to 4% from a previous 31% of patients reporting reactions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.